Pharmacovigilance data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has identified a substantially elevated risk of ischemic optic neuropathy (ION) associated with semaglutide 2.4 mg (Wegovy, Novo Nordisk) compared with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide 1.0 mg (Ozempic, Novo Nordisk), according to a newly published analysis in the British Journal of Ophthalmology. The findings carry particular clinical relevance given the accelerating prescribing rates of GLP-1 RAs across the United States and raise questions about whether current product labeling adequately reflects the ocular safety profile of this drug class.

The analysis, which reviewed 31,774 adverse event reports submitted to FAERS, identified a nearly fivefold higher risk of ION among patients receiving Wegovy compared with those receiving Ozempic. Although both formulations share the same active ingredient, semaglutide, the dose differential between the obesity indication (2.4 mg) and the type 2 diabetes mellitus indication (1.0 mg) appears to be a factor of consequence. Sex-based stratification of the data revealed that male patients carried a threefold higher ION risk relative to female patients, a disparity that warrants further mechanistic investigation.

ION refers to an interruption of blood supply to the optic nerve, resulting in acute or subacute monocular visual field loss. The non-arteritic anterior variant, non-arteritic anterior ischemic optic neuropathy (NAION), represents the most common form of acute optic neuropathy in adults over the age of 50 and is frequently associated with a “disc at risk” anatomical configuration, systemic vascular risk factors, and nocturnal hypotension. The condition carries no established restorative treatment and may result in permanent visual impairment. Given this prognosis, early recognition of pharmaceutical risk factors is a clinical priority.

The current FDA labeling for semaglutide-containing products does not list ION as a recognized adverse event. By contrast, the European Medicines Agency (EMA) has indicated that non-arteritic anterior ischemic optic neuropathy represents a very rare side effect of this drug class. The regulatory divergence between the FDA and the EMA on this point may reflect differing thresholds for label updates based on spontaneous reporting data, or may reflect differences in the populations captured by respective surveillance systems. Regardless, the disparity in labeling creates a practical challenge for prescribers who may be unaware of the potential association.

FAERS-based analyses carry methodological limitations that must be acknowledged. Spontaneous adverse event reporting is subject to underreporting, Weber bias, notoriety bias, and an inability to establish causality or calculate true incidence rates. The reporting population is not defined, denominator data are absent, and confounders such as baseline vascular disease, diabetes-related microvascular complications, and concurrent medications are not controlled. The authors of the British Journal of Ophthalmology analysis appear to have used disproportionality analysis, a standard pharmacovigilance methodology that generates reporting odds ratios rather than causal estimates. These limitations do not invalidate the signal, but they do constrain the strength of conclusions that can be drawn.

The clinical plausibility of a semaglutide-ION association is not without biological basis. GLP-1 receptors are expressed in retinal ganglion cells and the optic nerve, and preclinical data have demonstrated that GLP-1 RA activity influences intraocular pressure and retinal blood flow. Rapid reductions in hemoglobin A1c, which have been observed with both semaglutide formulations, may precipitate or unmask diabetic retinopathy progression through mechanisms that include altered retinal perfusion. Whether a parallel vascular mechanism operates at the optic nerve level, particularly at the higher doses used for weight management, remains an open question requiring prospective investigation.

The dose-dependence hypothesis is biologically coherent. The approved maintenance dose for Wegovy (2.4 mg subcutaneously once weekly) substantially exceeds that of Ozempic (maximum 2.0 mg, with 1.0 mg as the most widely used dose in diabetes management). Higher systemic exposure to semaglutide could theoretically produce greater hemodynamic fluctuations, altered autoregulation of optic nerve head perfusion, or amplified effects on the renin-angiotensin-aldosterone system, all of which have been implicated in NAION pathophysiology. The sex-based differential, with male patients at threefold higher risk, is also consistent with the known epidemiology of NAION, which disproportionately affects middle-aged men with small optic disc cup-to-disc ratios.

These findings arrive at a moment when the prescribing of semaglutide-based therapies has reached historically unprecedented levels. Wegovy received FDA approval in June 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Subsequent large-scale outcomes data, including results from the SELECT trial published in 2023, demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease, substantially expanding the therapeutic rationale for the drug beyond weight reduction alone. The ACC/AHA obesity management guidelines now recognize GLP-1 RAs as a class with meaningful cardiovascular benefit in high-risk patients, and prescribing volumes have scaled accordingly.

The cardiovascular benefit established in SELECT does not preclude the coexistence of an ophthalmologic risk signal. Benefit-risk assessment in clinical pharmacology routinely involves trade-offs between documented efficacy endpoints and lower-frequency adverse events. If the ION signal observed in FAERS reflects a true pharmacological effect, the absolute risk increase in any given patient may remain small even as the relative risk appears substantial. However, in a patient population that now numbers in the millions for Wegovy alone, even a rare adverse event frequency translates into a numerically notable burden of potentially irreversible visual loss.

From a clinical practice standpoint, these data suggest that prescribers should incorporate ophthalmologic history into the pre-prescribing evaluation for semaglutide, particularly for patients with known risk factors for NAION. These risk factors include small optic disc cup-to-disc ratio (disc at risk), hypertension, hyperlipidemia, obstructive sleep apnea, nocturnal hypotension, and a history of prior NAION in the contralateral eye. Patients in these categories may warrant baseline ophthalmology consultation before initiating Wegovy, and prompt referral upon any complaint of acute visual field loss or diminished visual acuity during treatment.

Novo Nordisk has not, based on publicly available information as of this writing, announced revisions to Wegovy prescribing information in response to this FAERS analysis. The FDA has not issued a drug safety communication specifically addressing ION risk for semaglutide products. Given the trajectory of the published literature and the volume of pharmacovigilance data now accumulating, regulatory review of the labeling question appears warranted.

The regulatory environment surrounding GLP-1 RAs has itself been subject to external pressures beyond pharmacovigilance concerns. The Trump administration’s most-favored nation (MFN) drug pricing initiative has introduced new dynamics into manufacturer pricing strategies, with at least one precedent now established in which a pharmaceutical company, Astellas Pharma, successfully argued before Japanese pricing authorities that domestic drug costs could be referenced against anticipated U.S. pricing pressure under the MFN framework. Astellas secured reimbursement pricing for its complement inhibitor Izervay that exceeded typical Japanese outcomes, with Chief Executive Officer Naoki Okamura characterizing the result as “relatively reasonable pricing” while acknowledging uncertainty about whether Japanese officials explicitly incorporated MFN considerations into their closed-door deliberations. Whether similar arguments will be deployed by GLP-1 RA manufacturers in international pricing negotiations remains an open question, though the Astellas precedent establishes proof of concept.

For clinicians managing patients on semaglutide therapy in Hawaii, the ION signal intersects with a patient population that carries elevated rates of obesity-associated cardiovascular risk factors, type 2 diabetes, and hypertension, all conditions that independently predispose to NAION. The appropriateness of routine ophthalmologic screening for patients initiating high-dose semaglutide has not been established by prospective trial data, and no professional society has issued formal guidance on this question. In the absence of such guidance, individual clinicians must exercise judgment informed by the available pharmacovigilance literature, the patient’s baseline ocular and vascular risk profile, and the documented cardiovascular benefits of the medication.

Prospective registry studies and, ideally, randomized controlled trial (RCT) substudies with pre-specified ophthalmologic endpoints will be necessary to characterize the ION risk with precision.